EMEA-000380-PIP07-20 - paediatric investigation plan

secukinumab
PIPHuman

Key facts

Invented name
Cosentyx
Active Substance
secukinumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0111/2021
PIP number
EMEA-000380-PIP07-20
Pharmaceutical form(s)
  • Powder for solution for injection
  • Solution for injection
Condition(s) / indication(s)
Treatment of thyroid eye disease
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com
Tel. +41 613241111

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page